ERBB2 and breast carcinoma: The doubling time for MC-BR-BTY-0019 was about 24–48 h, shorter than the commonly used HER2+ breast cancer cell lines such as SKBR3 (48–72 h (DSMZ)), MDA-MB-453 (50–60 h (DSMZ)), BT474 (100 h (DSMZ)), and MDA-MB-361 (103.2 h)24.